Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco Control
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
IASLC
Pembrolizumab Improves QOL Compared to Chemotherapy in NSCLC
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
The Trans-Pacific Partnership Agreement (TPPA) May Pose a Threat to Public Health
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.
Atezolizumab Improves Overall Survival Compared to Docetaxel in NSCLC
Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).
Icotinib Shows Progression-free Survival Benefit in NSCLC With Brain Metastases
Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).
Osimertinib in EGFR T790M-positive Non-small Cell Lung Cancer
Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.
Tumor, Node, and Metastasis Classification: 8th Edition Changes
The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.
International Cooperation Vital for Preventing Lung Cancer
Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.
Oncoviruses and Epigenetic Factors May Contribute to Risk of Developing Lung Cancer
Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.
Cabozantinib Safe and Effective in RET-rearranged Lung Cancer
Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in IASLC 2016
Loading... 
Loading...